Helixgate

Helixgate

Uncategorized

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

Read More

Published

on

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Lilly’s weight loss pill reaches brand new patients, even without full-court marketing press

Published

on

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.

Continue Reading

Uncategorized

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

Read More

Published

on

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

Read More

Continue Reading

Uncategorized

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

Read More

Published

on

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

Read More

Continue Reading
Advertisement

Trending